Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer-Reference-Cited by-同舟云学术

Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer

Published:2023-11-07 Issue: Volume: Page:
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Ahmed Mohamed E.^ORCID,Lee Matthew S.^ORCID,Mahmoud Ahmed M.^ORCID,Joshi Vidhu B.,Gopalakrishna Ajay,Bole Raevti,Haloi Rimki,Kendi A. Tuba,Bold Michael S.,Bryce Alan H.^ORCID,Karnes Robert Jeffrey,Kwon Eugene D.,Childs Daniel S.,Andrews Jack R.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

https://www.nature.com/articles/s41391-023-00751-6.pdf

Reference23 articles.

1. Baciarello G, Gizzi M, Fizazi K. Advancing therapies in metastatic castration-resistant prostate cancer. Expert Opin Pharmacother. 2018;19:1797–804.

2. Khoshkar Y, Westerberg M, Adolfsson J, Bill-Axelson A, Olsson H, Eklund M, et al. Mortality in men with castration-resistant prostate cancer-A long-term follow-up of a population-based real-world cohort. BJUI Compass. 2022;3:173–83.

3. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;2:389–96.

4. Ingrosso G, Detti B, Scartoni D, Lancia A, Giacomelli I, Baki M, et al. Current therapeutic options in metastatic castration-resistant prostate cancer. Semin Oncol. 2018;45:303–15.

5. FDA approves pluvicto/locametz for metastatic castration-resistant prostate cancer. J Nucl Med. 2022;63:13N.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peculiar Pattern of Response Following [225Ac]Ac-PSMA Therapy: A Case Report with ‘PSA Pseudoregression’ Response Pattern;Nuklearmedizin - NuclearMedicine;2024-05-17